31 October 2003
Award-winning building officially openened at Alderley Park
An award-winning £34million building, providing a new working environment for 750 office-based staff supporting AstraZeneca's global pharmaceuticals business, was officially opened at Alderley Park, Cheshire on Friday, 31 October. The ceremony was performed by John Patterson, AstraZeneca Executive Vice-President, Product Strategy and Licensing, who is also President of the Association of the British Pharmaceutical Industry (ABPI). The event was attended by employees and by local dignitaries.  More

05 February 2003
AstraZeneca announces a further $85m (£60.9m) investment
Largest single investment ever to be made at AstraZeneca's Alderley Park, Cheshire site AstraZeneca has announced an $85m (£60.9m) investment in a new cancer research building - its largest single investment to date at Alderley Park. It adds to previous investments at the site in state-of-the-art laboratory and office accommodation and site infrastructure, totalling over $250m (£180m) in the last three years More

22 October 2003
AstraZeneca Supports New Outreach and Mentoring Initiative for Underpriviliged Students
AstraZeneca is pleased to announce that it is donating £100,000 to the Brightside Trust, a charity that aims to help disadvantaged young people gain access to medicine and the healthcare professions.  The funding will be provided over three years and includes a one-year secondment to the organisation to work on its' Pathways to Medicine projects.  More

17 March 2003
AstraZeneca Makes Science More Interesting
Local primary school children can now enjoy their science lessons by having fun whilst learning, with help from AstraZeneca, Loughborough's medicines research and development company, who re-launched their science suitcases last week. The suitcases, designed to make science more appealing and inspiring to primary school children, are packed with interesting teaching aids, models, activities and games. More

10 January 2003
Local MP tours AstraZeneca's new facilities
An in-depth look at the state-of-the-art laboratory facilities on the AstraZeneca R&D Charnwood site, Loughborough's second largest employer with 1,200 staff was laid on for local MP Andy Reed last Friday (January 10). More

10 October 2003
Mysoline Press Statement
LONDON, 10th October 2003 - AstraZeneca UK today demonstrated its strong commitment to patients with CNS disorders with the announcement that we will be able to further extend the supply of Mysoline (primidone) within the UK through until the end of 2006.  More

01 September 2003
Mysoline Update
LONDON, 29 August 2003 - In early June 2003, AstraZeneca UK announced that it would be discontinuing the supply of 'Mysoline' (primidone), an AstraZeneca UK product that is indicated for use in epilepsy and essential tremor.  More